| 盐酸坦索罗辛缓释制剂的研究进展 |
| 投稿时间：2015-10-21 修订日期：2016-04-26 点此下载全文 |
| 引用本文：柴佩华,张涛,高申.盐酸坦索罗辛缓释制剂的研究进展[J].药学实践杂志,2016,34(6):493~496 |
| 摘要点击次数: 1620 |
| 全文下载次数: 2789 |
|
|
| 中文摘要:盐酸坦索罗辛广泛用于治疗良性前列腺增生症的下尿路症状，需要长期用药。口服盐酸坦索罗辛因药物吸收快、起效快，常导致低血压和眩晕等不良反应，故临床上建议应用其缓释制剂。目前国内外上市的盐酸坦索罗辛缓释制剂主要为缓释胶囊和缓释片，如Flomax®，Harnal®，国内仍以原研制剂Harnal®缓释胶囊占有主要市场，鉴于该药良好的市场前景，对其缓释制剂的研究也越来越多。本文就盐酸坦索罗辛缓释制剂的研究进展做一综述。 |
| 中文关键词:盐酸坦索罗辛 缓释制剂 |
| |
| Progress of tamsulosin hydrochloride sustained-release preparation |
|
|
| Abstract:Tamsulosin hydrochloride is widely used for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia, requiring long-term medication. It reduces adverse reactions of hypotension and dizziness by rapid absorption from oral intake. The sustained-release (SR) formulation is recommended for clinical application. Currently in domestic and foreign market, SR products mainly include SR capsules and SR tablets, like Flomax® and Harnal®. The domestic market mainly uses the originally developed Harnal® SR capsules. In accordance with the drug's potential market, more and more SR studies have been done. This article reviews the research progress of tamsulosin hydrochloride sustained-release preparation. |
| keywords:tamsulosin hydrochloride(TSH) sustained-release preparation |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
